None, “Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation (SPAF) in the 
Indonesian healthcare setting,” Fakultas Farmasi UGM, 2022.